In the fourth quarter, SpyGlass reported a net loss of $12.6 million, or $5.72 per share, compared to a net loss of $8.4 million, or $4.58 per share, in the same quarter of the previous year. For the full year, the net loss was $39.9 million, or $17.98 per share, compared to $29.2 million, or $16.31 per share, in 2024. The increase in losses is attributed to higher research and development expenses, which totaled $7.7 million for the fourth quarter and $29.2 million for the year, reflecting the company's investment in its Phase 3 trials for the Bimatoprost Drug Pad-IOL System (BIM-IOL System).
The company reported positive topline data from its Phase 1/2 trial of the BIM-IOL System, demonstrating significant intraocular pressure (IOP) control and a favorable safety profile. The results showed that 97% of trial participants were able to eliminate IOP-lowering eye drops, indicating the potential of the BIM-IOL System to transform treatment for glaucoma and ocular hypertension patients undergoing cataract surgery.
Looking ahead, SpyGlass is focused on completing enrollment in its ongoing Phase 3 trials and anticipates presenting additional clinical data at future medical meetings. The company is also preparing to initiate a first-in-human trial of the Bimatoprost Drug Ring System (BIM-DRS), which could further expand its market opportunities.
Overall, SpyGlass Pharma's strong financial position and promising clinical results position it well for future growth and success in the biopharmaceutical industry.
